Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Soluble Co‐Inhibitory Immune Checkpoint Molecules Are Increased in Patients With Polymyalgia Rheumatica Without Significant Correlations With Clinical Status: A Case‐Control Study
Hysa, Elvis , Camellino, Dario , Dejaco, Christian , Bauckneht, Matteo , Bagnasco, Marcello , Cutolo, Maurizio , Matteson, Eric L. , Cimmino, Marco A. , Saverino, Danièle , Cutolo, Maurizio , Dejaco, Christian , Pesce, Giampaola , Morbelli, Silvia

ACR Open Rheumatology | May 9, 2025 | Volume: 7 | Issue: 5 | Pages: No page available

10.1002/acr2.70045 | PMID 40344345 Get It

ObjectiveA dysregulated immune response is involved in the pathogenesis of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). These diseases have been reported as immune‐related adverse events in patients with cancer treated with immune checkpoints inhibitors. In this cross‐sectional study, the relationship between soluble immune checkpoint molecules (sICMs) and clinical/imaging features of PMR and GCA was investigated.MethodsConsecutive patients with PMR diagnosed according to the criteria by Bird et al were compared with age‐ and sex‐matched healthy controls. Patients with PMR and overlapping GCA had to also satisfy the 1990 ACR classification criteria for GCA. All patients underwent standardized clinical, laboratory examination, and 18F‐fluorodeoxyglucose positron emission tomography/computed tomography scans. The sICM anticytotoxic T Ly‐4, the programmed cell death protein 1 (PD‐1), and PD‐1 ligands PD‐L1 and PD‐L2 were measured by enzyme‐linked immunosorbent assay.ResultsForty patients (80% women, mean age 76 years, and mean disease duration 88 days) were assessed. Of these, 30 had isolated PMR and 10 had PMR with GCA. Patients showed significantly higher concentrations of all sICMs compared with controls (P < 0.001). Conditional logistic regression revealed the strong discriminative capacity of these molecules between patients and healthy controls, with PD‐1 showing complete separation among groups (effect size = 0.78) and PD‐L1 (odds ratio [OR] 134.33, P < 0.001) and PD‐L2 (OR 63.00, P < 0.001) demonstrating the strongest ability to distinguish patients from controls. Correlations between sICM levels and clinical features were generally weak or absent, with no significant differences based on disease phenotype or glucocorticoid exposure. Results were similar in glucocorticoid‐naive patients.ConclusionsICMs are significantly elevated in PMR and GCA and strongly differentiate patients from healthy controls. Although they do not correlate with clinical or imaging features, their consistent elevation in active disease might suggest a complex interplay between innate and adaptive immunity.image
Alterations of G-protein Activating Subunit Genes in Ovarian Hemangiomas: A Molecular Study of 6 Cases Including 3 Anastomosing Hemangiomas With a Cavernous Component
Dashti, Nooshin K. , Swanson, Amy A. , Keeney, Gary L., Edgar, Mark , Gupta, Sounak , Schoolmeester, John K., Edgar, Mark A. , Schoolmeester, John Kenneth

International Journal of Gynecological Pathology | May 9, 2025 | Volume: 45 | Issue: 1 | Pages: 79-81

10.1097/pgp.0000000000001107 | PMID 40341275 Get It

Aortoenteric Fistulas Following Endovascular Aortic Aneurysm Repair: A Review
Rey, Jorge , Bornak, Arash , Montoya, Christopher , Polania, Camilo A., Kang, Naixin , Sussman, Matthew , Gonzalez, Kathy , Polanía-Sandoval, Camilo , Polania, Camilo, Polania-Sandoval, Camilo A , Kenel-Pierre, Stefan C. , Sussman, Matthew, Erben, Young

Vascular and Endovascular Surgery | May 9, 2025 | Volume: 59 | Issue: 7 | Pages: 695-705

10.1177/15385744251339966 | PMID 40340624 Get It

Background Secondary aortoenteric fistulas (SAEF) following endovascular aortic repair (EVAR) is an extremely rare event but life threatening. Our review offers comprehensive knowledge on pathophysiology, clinical presentation, diagnosis, and treatment options. Aim To summarize the current literature regarding pathophysiology, clinical, diagnostic and therapeutic approach of aortoenteric fistulas secondary to EVAR. Methods We performed a literature search in Pubmed/MEDLINE to identify the literature published about SAEF after EVAR. Cases were summarized in a table and prevalences. Other relevant literature was included in the results sections. Results A total of 35 reports (single cases and small series) with 45 patients were included. SAEF after EVAR can result from infection, inflammation, or mechanical factors. Clinical presentation is often non-specific, ranging from a gastrointestinal herald bleed to hemorrhagic shock, or malaise and general infection-related symptoms. Cross-sectional imaging plays a critical role in diagnosing SAEF. The treatment approach involves a multidisciplinary team approach and requires broad-spectrum intravenous antibiotics, endovascular intervention for urgent hemorrhage control, and open surgical intervention for definitive repair. Long-term antimicrobial therapy is essential to avoid reinfection. Conclusions SAEF following EVAR represents a complex, life-threatening condition with limited evidence-based management strategies. Given the growing prevalence of endovascular procedures, comprehensive knowledge of SAEF is crucial for all health care providers to improve early diagnosis and outcomes.
Crescentic Glomerulonephritis Possibly Caused by COVID-19 Infection
Errabelli, Praveen , Lathiya, Maulik , Mareedu, Neeharik , Hernandez, Loren P. Herrera , Herrera Hernandez, Loren P, Errabelli, Praveen Kumar

Journal of Clinical Medicine | May 9, 2025 | Volume: 14 | Issue: 10 | Pages: 3302

10.3390/jcm14103302 | PMID 40429298 Get It

Background: The COVID-19 (coronavirus disease 2019) pandemic has presented a serious challenge to nephrologists, since it can lead to severe kidney injury in the form of acute tubular necrosis, with many patients requiring renal replacement therapy. This is predominantly seen in people who develop severe respiratory manifestations like ARDS (acute respiratory distress syndrome) from the viral infection, a cytokine storm or septic shock with unstable hemodynamics. It also presents with various glomerular injuries, mainly collapsing glomerulopathy in high-risk APOL1 (Apolipoprotein L1) genotype patients, thrombotic microangiopathy-related renal failure due to hyper coagulopathy and occasionally pauci-immune glomerulonephritis due to immune dysregulation. All the glomerular disorders that are caused by COVID-19 infection have been described under the designation COVAN (COVID-19-associated nephropathy). Proteinuria is a predominant presentation in glomerular disorders. Gross hematuria and AKI without any respiratory symptoms from COVID-19 infection have not been described so far in the literature. We are presenting one such rare case here. Methods: We have encountered a rare case of gross hematuria and severe acute renal failure. His serological work up was negative for all autoimmune etiologies that can cause Glomerulonephritis. He was found to have infection-related crescentic glomerulonephritis due to active COVID-19 infections discovered via kidney biopsy. He tested positive for SARS-CoV-2 but didn’t have any clinical respiratory symptoms. He has responded well to treatment with a steroid taper and antiviral medication (Remdesivir). This is a very rare renal manifestation of COVID-19 infection. Results: COVID-19 infection can result in crescentic glomerulonephritis. This can be diagnosed by kidney biopsy which shows extensive c3 deposits, tubuloreticular inclusion bodies along with crescentic lesions. This responds to treatment with steroids and Antiviral agents. Conclusions: Crescentic Glomerulonephritis should be considered as a possible etiology for severe acute kidney injury with hematuria in patients with active covid-19 infection without any respiratory symptoms. Kidney biopsy helps in diagnosing it and responds to treatment with steroids and antivirals.
The Impact of Delirium on Hospitalized Patients With COPD Exacerbation: Insights From the National In-Patient Sample
Ogbughalu, Pamela, Odeyemi, Yewande , Odeyemi, Yewande, Labban, Mohamad El , Odeyemi, Yewande

Respiratory Care | May 9, 2025 | Volume: 70 | Issue: 11 | Pages: 1423-1428

10.1089/respcare.12913 | PMID 40340545 Get It

Background: Delirium in hospitalized patients has been consistently associated with worse clinical outcomes, including increased mortality and prolonged hospital stays. COPD exacerbation is a common reason for hospitalization, and understanding the impact of delirium on this population is crucial for improving patient care and outcomes. Methods: We conducted a retrospective cohort study using the National In-Patient Sample dataset to assess the impact of delirium on patients hospitalized with COPD exacerbation. Subjects were identified using International Classification of Diseases, 10th Revision, codes for COPD exacerbation and delirium. Baseline characteristics and outcomes, including in-patient mortality and the use of invasive mechanical ventilation, were compared between subjects with and without delirium using chi-square analysis. Multivariate regression analysis was used to adjust for potential confounders. Results: A total of 8,062,333 subjects hospitalized with COPD exacerbation were included, of whom 574,005 (7.2%) had a diagnosis of delirium. Most subjects in both groups were white, covered by Medicare, and treated in large urban teaching hospitals. Subjects with delirium had higher rates of dementia, malnutrition, and chronic kidney disease. The rates of in-patient mortality (13.85% vs 4.29%, P < .01) and use of invasive mechanical ventilation (26.7% vs 7.79%, P < .01) were significantly higher in the delirium group. Delirium was associated with higher odds of mortality (adjusted odds ratio [aOR] 2.48, P < .01) and use of mechanical ventilation (aOR 3.92, P < .01). Subjects with delirium had longer and more costly hospital stays. Conclusions: Delirium was associated with worse outcomes in subjects hospitalized with COPD exacerbation.
Data Interoperability and Harmonization in Cardiovascular Genomic and Precision Medicine
Chahal, C. Anwar A. , Alahdab, Fares , Asatryan, Babken , Addison, Daniel , Aung, Nay , Chung, Mina K. , Denaxas, Spiros , Hall, Jennifer L. , Slotwiner, David J. , Vargas, Jose D. , Dunn, Jessilyn , Hall, Jennifer L , Pamir, Nathalie , Slotwiner, David J , Armoundas, Antonis A , Chahal, Choudhary Anwar A , Asatryan, Babken , Aung, Nay , Armoundas, Antonis A. , Alahdab, Fares

Circulation: Genomic and Precision Medicine | May 9, 2025 | Volume: 18 | Issue: 3 | Pages: No page available

10.1161/circgen.124.004624 | PMID 40340425 Get It

Despite advances in cardiovascular care and improved outcomes, fragmented healthcare systems, nonequitable access to health care, and nonuniform and unbiased collection and access to healthcare data have exacerbated disparities in healthcare provision and further delayed the technological-enabled implementation of precision medicine. Precision medicine relies on a foundation of accurate and valid omics and phenomics that can be harnessed at scale from electronic health records. Big data approaches in noncardiovascular healthcare domains have helped improve efficiency and expedite the development of novel therapeutics; therefore, applying such an approach to cardiovascular precision medicine is an opportunity to further advance the field. Several endeavors, including the American Heart Association Precision Medicine platform and public-private partnerships (such as BigData@Heart in Europe), as well as cloud-based platforms, such as Terra used for the National Institutes of Health All of Us, are attempting to temporally and ontologically harmonize data. This state-of-the-art review summarizes best practices used in cardiovascular genomic and precision medicine and provides recommendations for systems’ requirements that could enhance and accelerate the integration of these platforms.
Sensing of extracellular ATP via P2RX7 drives lung tumor growth through regulatory T cell suppressive function
Francisco, Ronaldo, Stoll, Carly R. , Cione, Marcos Pinheiro , Johnston, Tyler , Leff, Chloe , Souza, Fabio Carvalho de, Silva, Henrique Borges da , Santiago-Carvalho, Igor , de Gois Macedo, Bruna, Salgado, Caio Loureiro , Leff, Chloe Liliana, Junior, Ildefonso Silva, de Souza, Fabio Carvalho, Lancaster, Jessica N , da Silva, Henrique Borges, Borges da Silva, Henrique , Francisco, Ronaldo, Macedo, Bruna de Gois , White, Emily , Johnston, Tyler, Silva, Ildefonso , Souza, Fabio Carvalho de, Lima, Maria Regina D’Império , Lancaster, Jessica N.

No container title available | May 9, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.05.03.652022 | PMID 40654622 Get It

ABSTRACT Lung cancer is the leading cause of cancer-related deaths worldwide and, despite treatment advances, immune suppression remains an obstacle to effective therapy. Effector CD4 + T cells (CD4 + Teffs) are critical for antitumor immunity, but their function is often inhibited by regulatory T cells (Tregs), which accumulate in lung tumors and perform suppressive functions through multiple mechanisms. This suppression leads to tumor progression and poor patient outcomes. However, the mechanisms underlying Treg-mediated suppression are not fully understood. Here, we identify the extracellular ATP receptor P2RX7 as a key regulator of Treg function in lung tumors. Using a murine lung cancer model induced by Lewis lung carcinoma cells, we demonstrate that P2RX7 enhances the suppressive capacity of tumor-infiltrating Tregs, promoting tumor growth. In T cell-specific P2RX7-KO mice, reduced Treg infiltration was accompanied by increased CD4 + Teff accumulation and improved tumor control. Treg-specific P2RX7-KO mice exhibit reduced tumor growth, confirming a cell-intrinsic role of P2RX7 in Tregs. Suppression assays revealed that tumor-infiltrating WT Tregs have greater suppressive activity compared to P2RX7-KO Tregs, which failed to inhibit type 1 and Tfh-like responses. This was associated with increased tumor-specific IgG production by lung B cells in P2RX7-KO mice. We also observed that WT Tregs express higher levels of the immunosuppressive surface molecule CTLA-4 when compared to P2RX7-KO Tregs. In summary, we show that P2RX7 expression on Tregs is essential for their suppressive function in lung cancer, and targeting of P2RX7 may constitute a novel strategy to improve lung cancer treatment by alleviating Treg-mediated immune suppression.
Epilepsy
Burkholder, David B. , Wirrell, Elaine

Seminars in Neurology | May 8, 2025 | Volume: 45 | Issue: 02 | Pages: 178-179

10.1055/a-2556-8487 Get It

Aqueous Humor Dynamics Changes and Predictors of IOP Response to Latanoprost in Healthy Subjects
Kazemi, Arash , Reitinger, Jeremy C. , Gulati, Vikas , Fan, Shan , Sit, Arthur J. , Sit, Arthur J , Toris, Carol B. , Reed, David M. , Moroi, Sayoko E.

Journal of Glaucoma | May 8, 2025 | Volume: 34 | Issue: 12 | Pages: 1056-1064

10.1097/ijg.0000000000002585 | PMID 40341017 Get It

Précis: In our study of the factors predictive of latanoprost response, we found that normotensive subjects with higher intraocular pressure, lower uveoscleral outflow, and higher body mass index had a greater response to 1-week treatment. Purpose: To evaluate relationships between variable intraocular pressure (IOP) responses to latanoprost and participant characteristics, baseline values and changes in aqueous humor dynamics (AHD) parameters. Methods: We assessed 226 eyes from 113 healthy participants. AHD parameters measured at baseline and after 1-week treatment with latanoprost included: IOP by pneumatonometry, episcleral venous pressure (EVP) by venomanometry, aqueous humor flow rate by fluorophotometry, outflow facility by 2-minute pneumatonography, and uveoscleral outflow calculated using the modified Goldmann equation. IOP responses were categorized into 4 groups: nonresponders (<10% reduction), all-responders (≥10% reduction), medium-responders (10%–20% reduction), and high-responders (≥20% reduction). Generalized estimating equation models were used to analyze treatment effects and compare groups. Results: Baseline IOP was higher in high-responders than medium-responders and nonresponders ( P =0.007 and P <0.001, respectively). Body mass index (BMI) was significantly higher in high-responders and all-responders compared with nonresponders ( P =0.02 and P =0.03, respectively). Responders had lower baseline uveoscleral outflow ( P =0.03). There were no significant differences in other baseline characteristics including EVP, outflow facility, and aqueous flow rate between the 4 groups. IOP decreased while outflow facility and uveoscleral outflow increased after latanoprost treatment in all responder groups but did not change in nonresponders. EVP and aqueous flow rate did not change significantly in any group. The change in uveoscleral outflow was greater in high-responders than in nonresponders ( P =0.004). Conclusions: In healthy subjects, higher baseline IOP, lower uveoscleral outflow and higher BMI are predictors of a greater IOP reduction by latanoprost. A greater increase in uveoscleral outflow is responsible for this larger response.
Myelodysplastic neoplasm with biallelic TP53 inactivation in a patient with plasma cell myeloma after cytotoxic therapy
He, Rong , Chen, Dong

Blood | May 8, 2025 | Volume: 145 | Issue: 19 | Pages: 2230-2230

10.1182/blood.2024028288 | PMID 40338571 Get It